GHSR deficiency exacerbates Parkinson's disease pathology by impairing autophagy
- PMID: 39180981
- PMCID: PMC11388265
- DOI: 10.1016/j.redox.2024.103322
GHSR deficiency exacerbates Parkinson's disease pathology by impairing autophagy
Abstract
In Parkinson's disease (PD), exogenous ghrelin protects dopaminergic neurons through its receptor, growth hormone secretagogue receptor (GHSR). However, in contrast to the strikingly low levels of ghrelin, GHSR is highly expressed in the substantia nigra (SN). What role does GHSR play in dopaminergic neurons is unknown. In this study, using GHSR knockout mice (Ghsr-/- mice) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model, we found that GHSR deletion aggravated dopaminergic neurons degeneration, and the expression and activity of GHSR were significantly reduced in PD. Furthermore, we explored the potential mechanism that GHSR deficiency aggregated PD-related neurodegeneration. We showed that DEPTOR, a subunit of mTORC1, was overexpressed in Ghsr-/- mice, positively regulating autophagy and enhancing autophagy initiation. The expression of lysosomal markers was abnormal, implying lysosomal dysfunction. As a result, the damaged mitochondria could not be effectively eliminated, which ultimately exacerbated the injury of nigral dopaminergic neurons. In particular, we demonstrated that DEPTOR could be transcriptionally regulated by KLF4. Specific knockdown of KLF4 in dopaminergic neurons effectively alleviated neurodegeneration in Ghsr-/- mice. In summary, our results suggested that endogenous GHSR deletion-compromised autophagy by impairing lysosomal function, is a key contributor to PD, which provided ideas for therapeutic approaches involving the manipulation of GHSR.
Keywords: Autophagy; DEPTOR; GHSR; KLF4; Parkinson's disease.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Figures








References
-
- Goldman S.M. Environmental toxins and Parkinson's disease. Annu. Rev. Pharmacol. Toxicol. 2014;54:141–164. - PubMed
-
- Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet. 2004;363(9423):1783–1793. - PubMed
-
- Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272. - PubMed
-
- Song N., et al. Assessments of plasma ghrelin levels in the early stages of Parkinson's disease. Mov. Disord. 2017;32(10):1487–1491. - PubMed
-
- Yu J., et al. Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis. Neuropeptides. 2016;56:69–74. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials